Rosiglitazone is effective to improve renal damage in type-1-like diabetic rats.

Huang, K-C; Cherng, Y-G; Chen, L-J; Hsu, C-T; Cheng, J-T

Huang, K-C; Cherng, Y-G; Chen, L-J; Hsu, C-T; Cheng, J-T.

Afiliação

Huang KC; Department of Nephrology, Chi-Mei Medical Center, Liou Ying, Tainan City, Taiwan.
Cherng YG; Department of Anesthesiology, Shuang Ho Hospital, New Taipei City, and Department of Anesthesiology, College of Medicine, Taipei Medical University, Taiwan.
Chen LJ; Institute of Basic Medical Science, College of Medicine, National Cheng Kung University, Tainan City, Taiwan.
Hsu CT; Department of Pathology, Edah University Medical Center, Yanchao, Kaohsiung City, Taiwan.
Cheng JT; Department of Medical Research, Chi-Mei Medical Center, Yong Kang, Tainan City, Taiwan.

Horm Metab Res ; 46(4): 240-4, 2014 Apr.

Article em En | MEDLINE | ID: mdl-24136780

Assuntos

Diabetes Mellitus Experimental/tratamento farmacológico; Diabetes Mellitus Experimental/patologia; Diabetes Mellitus Tipo 1/tratamento farmacológico; Diabetes Mellitus Tipo 1/patologia; Nefropatias Diabéticas/tratamento farmacológico; Rim/patologia; Tiazolidinedionas/uso terapêutico; Animais; Diabetes Mellitus Experimental/metabolismo; Nefropatias Diabéticas/metabolismo; Nefropatias Diabéticas/patologia; Glucuronidase/metabolismo; Rim/efeitos dos fármacos; Proteínas Klotho; Masculino; PPAR gama/metabolismo; Ratos Wistar; Receptor Tipo 1 de Fator de Crescimento de Fibroblastos/metabolismo; Rosiglitazona; Tiazolidinedionas/farmacologia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tiazolidinedionas / Diabetes Mellitus Experimental / Diabetes Mellitus Tipo 1 / Nefropatias Diabéticas / Rim Limite: Animals Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google